
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.
Publication
, Journal Article
Alikhan, A; Sayed, C; Alavi, A; Alhusayen, R; Brassard, A; Burkhart, C; Crowell, K; Eisen, DB; Gottlieb, AB; Hamzavi, I; Hazen, PG; Jaleel, T ...
Published in: J Am Acad Dermatol
July 2019
Hidradenitis suppurativa is a severe and debilitating dermatologic disease. Clinical management is challenging and consists of both medical and surgical approaches, which must often be combined for best outcomes. Therapeutic approaches have evolved rapidly in the last decade and include the use of topical therapies, systemic antibiotics, hormonal therapies, and a wide range of immunomodulating medications. An evidence-based guideline is presented to support health care practitioners as they select optimal medical management strategies and is reviewed in this second part of the management guidelines. A therapeutic algorithm informed by the evidence available at the time of the review is provided.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Am Acad Dermatol
DOI
EISSN
1097-6787
Publication Date
July 2019
Volume
81
Issue
1
Start / End Page
91 / 101
Location
United States
Related Subject Headings
- United States
- Treatment Outcome
- Risk Assessment
- Prognosis
- Practice Guidelines as Topic
- North America
- Male
- Injections, Intralesional
- Immunosuppressive Agents
- Humans
Citation
APA
Chicago
ICMJE
MLA
NLM
Alikhan, A., Sayed, C., Alavi, A., Alhusayen, R., Brassard, A., Burkhart, C., … Poulin, Y. (2019). North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol, 81(1), 91–101. https://doi.org/10.1016/j.jaad.2019.02.068
Alikhan, Ali, Christopher Sayed, Afsaneh Alavi, Raed Alhusayen, Alain Brassard, Craig Burkhart, Karen Crowell, et al. “North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.” J Am Acad Dermatol 81, no. 1 (July 2019): 91–101. https://doi.org/10.1016/j.jaad.2019.02.068.
Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91–101.
Alikhan, Ali, et al. “North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.” J Am Acad Dermatol, vol. 81, no. 1, July 2019, pp. 91–101. Pubmed, doi:10.1016/j.jaad.2019.02.068.
Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, Crowell K, Eisen DB, Gottlieb AB, Hamzavi I, Hazen PG, Jaleel T, Kimball AB, Kirby J, Lowes MA, Micheletti R, Miller A, Naik HB, Orgill D, Poulin Y. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91–101.

Published In
J Am Acad Dermatol
DOI
EISSN
1097-6787
Publication Date
July 2019
Volume
81
Issue
1
Start / End Page
91 / 101
Location
United States
Related Subject Headings
- United States
- Treatment Outcome
- Risk Assessment
- Prognosis
- Practice Guidelines as Topic
- North America
- Male
- Injections, Intralesional
- Immunosuppressive Agents
- Humans